Myomo (NYSEAMERICAN:MYO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $9.90 million for the quarter.
Myomo Stock Performance
MYO stock opened at $4.80 on Tuesday. Myomo has a 1-year low of $2.51 and a 1-year high of $7.17. The firm has a market capitalization of $145.20 million, a price-to-earnings ratio of -20.87 and a beta of 1.68.
Wall Street Analyst Weigh In
MYO has been the topic of several research analyst reports. Ascendiant Capital Markets boosted their price objective on Myomo from $8.50 to $9.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum boosted their price objective on Myomo from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.50 price objective on shares of Myomo in a research report on Wednesday, November 13th.
About Myomo
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
Featured Stories
- Five stocks we like better than Myomo
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Investing in Construction Stocks
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.